Assertio Therapeutics, formerly known as Depomed, will pay $3.6m to settle charges that it caused false claims to be submitted to Medicare and TRICARE when it targeted its advertising at pain specialists who were prescribing high volumes of products similar to its product Lazanda, a nasal spray that contains fentanyl.
Assertio Therapeutics dinged $3.6m over fentanyl false claims
The settlement is the latest in a string of False Claims Act enforcement actions against pharmaceutical companies.